抗发炎治疗药物市场规模、份额和成长分析（按药物类别、适应症、用途、通路和地区划分）－2026-2033年产业预测

预计到 2024 年，全球抗发炎治疗市场规模将达到 1,073.2 亿美元，到 2025 年将达到 1,124.7 亿美元，到 2033 年将达到 1,636.5 亿美元，预测期（2026-2033 年）的复合年增长率为 4.8%。

由于类风湿性关节炎、气喘和发炎性肠道疾病（IBD）等自体免疫疾病和慢性发炎性疾病的盛行率不断上升，全球抗发炎治疗市场正经历显着增长。这些疾病给全球医疗保健系统带来了持续的负担。生物製药和标靶治疗显着改善了治疗效果，而生物相似药则提高了成本效益，并改善了患者获得先进疗法的机会。生物相似药驱动的市场竞争动态有助于减轻患者负担，并拓宽治疗选择。此外，慢性发炎患者老年人口的成长预计将进一步推动市场需求。在研製生物製药（尤其是针对白细胞介素路径的生物製剂）的持续研发和潜在核准，可望支持市场的长期扩张，并促进抗发炎治疗向精准医疗的转变。

全球抗发炎治疗市场驱动因素

全球抗发炎治疗市场受到自体免疫疾病（例如发炎性肠道疾病 (IBD)、干癣、气喘和类风湿性关节炎）日益普遍的显着影响。光是关节炎就影响着数百万人，推动了对先进治疗方案的需求。不断增长的患者群体凸显了有效治疗方案的紧迫性。因此，生物製药及其生物相似药在全球范围内的接受度不断提高，反映出人们正转向采用更先进、更具标靶性的治疗方法来有效治疗这些致残性疾病。因此，在不断增长的患者需求的推动下，预计该市场将持续成长。

限制全球抗发炎治疗市场发展的因素

全球抗发炎治疗市场面临严峻挑战，生物製药治疗费用高昂，限制了患者的用药途径，尤其是在中低收入国家。诸如阿达木单抗（Humira）和其他生物製药的年度治疗费用可能非常高昂，令许多患者难以负担。即使生物相似药问世，治疗费用仍是患者获得治疗的一大障碍。此外，保险覆盖范围的不均衡和报销流程的延误加剧了这些用药难题，导致全球许多患者无法及时获得适当的治疗，最终阻碍了抗发炎疗法在市场上的整体发展。

全球抗发炎治疗药物市场趋势

全球抗发炎治疗市场正日益呈现以标靶特定发炎路径的工程化生物目标和先进小分子药物为特征的趋势。 IL-23抑制剂、JAK抑制剂和FcRn标靶抗体等创新药物正在推动治疗策略从传统免疫抑制剂转向其他疗法，并将治疗范围从罕见自体免疫疾病扩展到溃疡性大肠炎等更常见的疾病。这一趋势不仅提高了疗效并最大限度地减少了副作用，而且随着现有产品面临来自学名药和生物相似药日益激烈的竞争，也带来了巨大的商业性机会。因此，市场正朝着精准医疗的方向发展，有望实现更有效、更有针对性的发炎性疾病管理。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球抗发炎治疗药物市场规模（依药物类别划分）及复合年增长率（2026-2033 年）

• 抗发炎生物製药
• 非类固醇消炎剂（NSAIDs）
• 皮质类固醇

全球抗发炎治疗药物市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 关节炎
• 呼吸系统疾病
• 多发性硬化症
• 银屑病
• 发炎性肠道疾病

全球抗发炎治疗药物市场规模（按应用领域划分）及复合年增长率（2026-2033 年）

• 自体免疫疾病
• 发炎性疾病
• 呼吸系统疾病

全球抗发炎治疗药物市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房

全球抗发炎治疗药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• AbbVie（USA）
• Johnson & Johnson（USA）
• Pfizer（USA）
• F. Hoffmann-La Roche（Switzerland）
• Novartis（Switzerland）
• Merck & Co., Inc.（USA）
• AstraZeneca（UK/Sweden）
• Bristol Myers Squibb（USA）
• Amgen（USA）
• Eli Lilly and Company（USA）
• Sanofi（France）
• GSK（GlaxoSmithKline）（UK）
• Bayer（Germany）
• Gilead Sciences（USA）
• Takeda Pharmaceutical Company（Japan）
• Teva Pharmaceutical Industries（Israel）
• Boehringer Ingelheim（Germany）
• Regeneron Pharmaceuticals（USA）
• Viatris（USA）
• UCB（Belgium）

结论与建议

Global Anti-Inflammatory Therapeutics Market size was valued at USD 107.32 Billion in 2024 and is poised to grow from USD 112.47 Billion in 2025 to USD 163.65 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The global anti-inflammatory therapeutics market is witnessing significant growth due to a rising prevalence of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD), which consistently burden health systems worldwide. Biologics and targeted therapies have greatly improved treatment outcomes, while biosimilars introduce cost-effectiveness and greater accessibility to advanced treatments. Competitive market dynamics driven by biosimilars have led to reduced patient costs and increased options for therapies. Additionally, the aging population experiencing chronic inflammation is expected to further elevate demand. Ongoing development and anticipated approvals of pipeline biologics, particularly those targeting interleukin pathways, are set to bolster long-term market expansion and facilitate a shift toward precision medicine in anti-inflammatory treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Inflammatory Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Inflammatory Therapeutics Market Segments Analysis

Global Anti-Inflammatory Therapeutics Market is segmented by Drug Class, Indication, Application, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids. Based on Indication, the market is segmented into Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. Based on Application, the market is segmented into Autoimmune, Inflammatory Diseases and Respiratory Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is significantly influenced by the growing prevalence of autoimmune and chronic inflammatory conditions such as inflammatory bowel disease (IBD), psoriasis, asthma, and rheumatoid arthritis. With millions of individuals affected by arthritis alone, there is an escalating demand for advanced therapeutic solutions. This rise in patient populations underscores the urgent need for effective treatment options. As a result, biologics and their biosimilars are increasingly being embraced globally, reflecting a shift toward more sophisticated and targeted therapies to address these debilitating diseases effectively. The market is thus positioned for continued growth fueled by this rising patient demand.

Restraints in the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market faces significant challenges due to the high costs associated with biologic treatments, which limit patient access, particularly in low- to medium-income countries. The financial burden for therapies, such as Humira and other biologics, can reach astronomical figures annually, making them unaffordable for many. Even with the introduction of biosimilars, the issue of affordability persists, creating barriers to treatment. Furthermore, inconsistent insurance coverage and slow reimbursement processes exacerbate these accessibility problems, leaving numerous patients globally without timely or adequate care, ultimately hindering the overall progress of anti-inflammatory therapies in the market.

Market Trends of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is increasingly characterized by the emergence of targeted biologics and sophisticated small molecules designed to address specific inflammatory pathways. Innovations such as IL-23 inhibitors, JAK inhibitors, and FcRn-targeting antibodies are directing a shift away from traditional immunosuppressants, expanding the applicability of treatments from rare autoimmune disorders to more common conditions like ulcerative colitis. This trend not only enhances therapeutic efficacy and minimizes side effects but also presents significant commercial opportunities as established products face mounting competition from generics and biosimilars. As a result, the market is evolving towards precision medicine, promising a more effective and targeted management of inflammatory diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anti-Inflammatory Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Anti-Inflammatory Biologics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids

Global Anti-Inflammatory Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Arthritis
• Respiratory Diseases
• Multiple Sclerosis
• Psoriasis
• Inflammatory Bowel Disease

Global Anti-Inflammatory Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Autoimmune
• Inflammatory Diseases
• Respiratory Diseases

Global Anti-Inflammatory Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy

Global Anti-Inflammatory Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Indication, Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations